Oncology

Camrelizumab/rivoceranib significantly prolongs OS, PFS in unresectable HCC

Camrelizumab plus rivoceranib (apatinib) significantly prolonged overall survival (OS) and progression-free survival (PFS), and improved overall response rate (ORR) for the treatment of unresectable hepatocellular carcinoma (uHCC) compared with the standard first-line treatment, sorafenib, according to a press release. This is the first positive pivotal trial to show survival benefits with...